These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28811469)

  • 1. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
    Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
    Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth.
    Seidi K; Jahanban-Esfahlan R; Monhemi H; Zare P; Minofar B; Daei Farshchi Adli A; Farajzadeh D; Behzadi R; Mesgari Abbasi M; Neubauer HA; Moriggl R; Zarghami N; Javaheri T
    Oncogene; 2018 Jul; 37(29):3967-3980. PubMed ID: 29662195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
    Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
    Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor.
    Li J; Ji J; Holmes LM; Burgin KE; Barton LB; Yu X; Wagner TE; Wei Y
    Cancer Gene Ther; 2004 May; 11(5):363-70. PubMed ID: 15044960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma].
    Huang ZJ; Luo Q; Yan JH; Wang SY
    Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice.
    Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Farajzadeh D; Behzadi R; Zarghami N
    Adv Pharm Bull; 2021 Feb; 11(2):385-392. PubMed ID: 33880362
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)₃-tTF.
    Huang ZJ; Zhao Y; Luo WY; You J; Li SW; Yi WC; Wang SY; Yan JH; Luo Q
    ScientificWorldJournal; 2013; 2013():637086. PubMed ID: 23861656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo.
    Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ
    Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction.
    Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S
    Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.
    Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J
    Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of fusion proteins for selective occlusion of tumor vessels.
    Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
    Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor vascular infarction: prospects and challenges.
    Jahanban-Esfahlan R; Seidi K; Zarghami N
    Int J Hematol; 2017 Mar; 105(3):244-256. PubMed ID: 28044258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer.
    Zhang X; Cheung RM; Komaki R; Fang B; Chang JY
    Clin Cancer Res; 2005 Sep; 11(18):6657-68. PubMed ID: 16166445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
    Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
    Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide.
    Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG
    Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis.
    Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL
    Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.